Zdrowie i gospodarka · 18/07/2003

FDA Approves Supplemental New Animal Drug Application for Laidlomycin

The US Food and Drug Administration (FDA) is updating its animal drug regulations to reflect the approval of a supplemental new animal drug application (NADA) filed by Alpharma Inc., which allows for the presence of residues of laidlomycin in cattle liver, and codifies the previously established acceptable daily intake (ADI) for total residues of laidlomycin.